Pluri Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)0.77 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $1.03Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $12.7M Shares Outstanding 12.3M diluted All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Pluri Inc. is transitioning from a clinical-stage research entity to a commercial-stage biotechnology company, highlighted by the June 2026 U.S. cosmetic product listings of its regenerative aesthetic products, Regenativo+ and Placento+, through its subsidiary Cellav. However, the company faces severe near-term liquidity pressures, including ongoing negotiations with the European Investment Bank (EIB) regarding the repayment terms of a €20 million loan originally due on June 1, 2026, and a Nasdaq non-compliance notice regarding its minimum market value of listed securities. While its proprietary 3D cell-expansion platform holds significant long-term potential across therapeutics, foodtech, and agtech, the persistent cash burn and immediate financial overhang warrant a cautious Hold stance until financing terms are stabilized and initial commercial revenues materialize. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario Negotiations with the EIB break down, leading to potential enforcement actions or highly dilutive emergency equity raises to cover the €20 million obligation. U.S. commercial adoption of Cellav's aesthetic products is slower than expected, and the company fails to regain compliance with Nasdaq listing standards, resulting in a delisting to OTC markets and severe downward pressure on the share price. Base CaseCentral scenario The company successfully negotiates an extension or restructuring of its €20 million EIB loan before the July 3, 2026 deadline, avoiding immediate enforcement actions. Cellav begins generating high-margin, near-term commercial revenues in the U.S. regenerative aesthetics market, helping to offset the ongoing R&D cash burn. The stock maintains its Nasdaq listing as market capitalization stabilizes above the compliance threshold. Bull CaseUpside scenario Successful commercial launch of Cellav's aesthetic products in the U.S. and UK, combined with a favorable restructuring of the €20 million EIB loan, which would alleviate immediate going concern pressures and validate the commercial viability of Pluri's 3D cell expansion platform. Scenarios reflect our research view at the research date. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |